GLP-1 receptor agonists may reduce the risk of obesity-related cancers in patients with type 2 diabetes by 7% compared to DPP-4 inhibitors. The study involved 170,030 adults with T2D and obesity, ...
The overwhelming popularity of GLP-1 drugs – what President Trump calls “the fat shot” – has insurance companies scrambling to satisfy consumer access to the treatments while at the same time reining ...
A new study hints that pregnant people who have previously taken drugs like Ozempic may face a higher risk of certain poor pregnancy outcomes. But more studies are needed to understand the finding.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback